Insight

Guilherme Nader Marta: RWE is becoming increasingly vital in cancer research

medimix.be

Dec 6, 2024, 17:13

Guilherme Nader Marta: RWE is becoming increasingly vital in cancer research

Guilherme Nader Marta, Clinical Fellow at Dana-Farber Cancer Institute, shared a post on X:

“RWE is becoming increasingly vital in cancer research.

To improve quality, we need to understand where we stand.

Happy to share this major effort analyzing 1251 studies mapping RWE.

Standardization and increase in collaboration will be key to increase the relevance of RWD.”

Guilherme Nader Marta

Characteristics and impact of real-world evidence studies in oncology: comprehensive mapping review of publications evaluating targeted therapies in solid tumours

Authors: A. Pellat, T. Grinda, P. Cresta Morgado, A. Prelaj, V. Miskovic, A. Valachis, I. Zerdes, D. Martins-Branco, L. Provenzano, A. Spagnoletti, G. Nader-Marta, B.E. Wilson, Y.-H. Yang, G. Pentheroudakis, S. Delaloge, L. Castelo-Branco, M. Koopman

Guilherme Nader Marta

A Prelaj A. Pellat A. Spagnoletti A. Valachis B.E. Wilson cancer Cancer research D. Martins Branco Dana-Farber Cancer Institute G Pentheroudakis G. Nader-Marta Guilherme Nader Marta I. Zerdes L. Castelo-Branco L. Provenzano M. Koopman OncoDaily Oncology P. Cresta Morgado RWD S. Delaloge T. Grinda V. Miskovic Y.-H. Yang

VERITAC-2 Trial Update: Vepdegestrant Meets Primary Endpoint in ESR1-Mutant Breast Cancer

New Paper Alert: HARMONi-2 study of Ivonescimab vs pembrolizumab for PD-L1-positive non-small cell lung cancer

We are thrilled to welcome Dr. Jasmine Kamboj to the OncoDaily Editorial Board!

Oncologist Near Me – Fedro Alessandro Peccatori: Leading Expert in Gynecological Oncology

MATTERHORN trial - FLOT plus durvalumab will become the new standard of care in the preoperative setting for gastroesophageal cancer